Growing incidences of SUI to drive Europe Urethral Bulking Systems Market
A urethral bulking system is abreast with single use, sterile components for the urethral injection to treat SUI (stress urinary incontinence) owing to ISD (intrinsic sphincter deficiency) in grown-up women having stress predominant mixed incontinence.
What are the market dynamics?
Europe is subject to stress, embarrassment, and discomfort pertaining to urinary incontinence, in social gatherings, in particular. This is the major factor driving Europe urethral bulking systems market as of now and the scenario is expected to continue even going forward, with the only difference being – preventive course of action to take over the curative course of action in the near future. Persistence Market Research has delved deep into this aspect and tabled the insights pertaining to the same in its market study entitled “Europe Urethral Bulking Systems Market”.
Persistence Market Research has categorized Europe Urethral Bulking Systems Market by product as pyrolytic carbon-coated graphite beads, calcium hydroxylapatite-based, polydimethylsiloxane macroparticle, polyacrylamide hydrogel, and hyaluronic acid-based. End-user-wise, it’s ASCs (Ambulatory Surgical Centers), specialty clinics, and hospitals. It has further stated that pyrolytic carbon-coated graphite beads hold the largest market share with cost-effectiveness being at the forefront. By end-user, it’s ASCs ruling the roost. By type, it’s non-endoscopic and endoscopic.
At the same time, complications like urethral prolapse, sub-urethral abscess, and particle migration are likely to restrain the market for urethral bulking systems in Europe.
Get To Know More – https://www.persistencemarketresearch.com/samples/32668
The Key Stakeholders
Persistence Market Research has profiled the key market players as follows:
- Boston Scientific Corporation
- Coloplast Corporation
- Axonics Modulation Technologies, Inc. (Contura Inc.)
- Palette Life Sciences, Inc.
- Laborie, Inc.
Persistence Market Research has entailed that Axonics Modulation Technologies, Inc., in February 2021, completed acquisition of Contura (UK-based), along with its lead product named Bulkamid. It comes across as one of the urethral bulking agent used for treating female SUI. It has gone further stating that Laborie, Inc., in April 2019, did acquire Cogentix Medical for expanding the product portfolio, thereby strengthening the stress urinary incontingence and overactive bladder segment.
That was about the inorganic mode of expansion. Coming to organic expansion, Persistence Market Research has mentioned that Axonics Modulation Technologies, Inc., in March 2021, inked an agreement with Micro Systems Technologies for producing a neuromodulation device. Besides, Boston Scientific Corporation, in June 2019, did unveil expansion of a novel Equipment Technology Centre at in Galway at Ballybrit site.
In all, Europe Urethral Bulking Systems Market is all set to usher the technological advancements in the forecast period – Persistence Market Research.